HK1219415A1 - 聯苯化合物的結晶游離碱形式 - Google Patents
聯苯化合物的結晶游離碱形式Info
- Publication number
- HK1219415A1 HK1219415A1 HK16107421.6A HK16107421A HK1219415A1 HK 1219415 A1 HK1219415 A1 HK 1219415A1 HK 16107421 A HK16107421 A HK 16107421A HK 1219415 A1 HK1219415 A1 HK 1219415A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- biphenyl compound
- crystalline freebase
- freebase forms
- forms
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22580309P | 2009-07-15 | 2009-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1219415A1 true HK1219415A1 (zh) | 2017-04-07 |
Family
ID=42562758
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12108950.7A HK1168050A1 (zh) | 2009-07-15 | 2012-09-13 | 聯苯化合物的結晶游離碱形式 |
HK16107421.6A HK1219415A1 (zh) | 2009-07-15 | 2016-06-24 | 聯苯化合物的結晶游離碱形式 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12108950.7A HK1168050A1 (zh) | 2009-07-15 | 2012-09-13 | 聯苯化合物的結晶游離碱形式 |
Country Status (21)
Country | Link |
---|---|
US (11) | US8541451B2 (zh) |
EP (2) | EP2453894B1 (zh) |
JP (4) | JP5651174B2 (zh) |
KR (1) | KR101742252B1 (zh) |
CN (1) | CN102470130B (zh) |
AU (1) | AU2010273514B2 (zh) |
BR (1) | BR112012000890A2 (zh) |
CA (2) | CA2765621C (zh) |
DK (1) | DK2453894T3 (zh) |
ES (2) | ES2639642T3 (zh) |
HK (2) | HK1168050A1 (zh) |
HR (1) | HRP20151344T1 (zh) |
HU (1) | HUE026414T2 (zh) |
IL (1) | IL216995A (zh) |
MX (1) | MX2012000682A (zh) |
PL (2) | PL2987490T3 (zh) |
PT (1) | PT2453894E (zh) |
SG (2) | SG178036A1 (zh) |
SI (1) | SI2453894T1 (zh) |
SM (1) | SMT201600019B (zh) |
WO (1) | WO2011008809A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
CA2765621C (en) | 2009-07-15 | 2018-02-13 | Theravance, Inc. | Crystalline freebase forms of a biphenyl compound |
SG186708A1 (en) * | 2010-07-13 | 2013-02-28 | Theravance Inc | Process for preparing a biphenyl-2-ylcarbamic acid |
DK2958916T3 (en) * | 2013-02-21 | 2018-11-12 | Pfizer | Solid forms of a selective CDK4 / 6 inhibitor |
WO2015070366A1 (en) | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
CN112694434B (zh) * | 2020-12-29 | 2023-06-16 | 浙江和泽医药科技股份有限公司 | 一种雷芬那辛新中间体及其活性亲电砌块和雷芬那辛的新制备方法 |
WO2023104920A1 (en) | 2021-12-09 | 2023-06-15 | Medichem, S.A. | Crystalline acetone solvate of revefenacin |
CN114276290B (zh) * | 2021-12-24 | 2024-05-28 | 浙江和泽医药科技股份有限公司 | 一种雷芬那辛无水晶型及其制备方法 |
CN117263849A (zh) * | 2023-09-19 | 2023-12-22 | 山东京卫制药有限公司 | 一种雷芬那辛三水合物晶型及其制备方法 |
CN117263848A (zh) * | 2023-09-19 | 2023-12-22 | 山东京卫制药有限公司 | 一种雷芬那辛的吸入喷雾剂 |
CN117180235A (zh) * | 2023-09-19 | 2023-12-08 | 山东京卫制药有限公司 | 一种无定型雷芬那辛吸入制剂 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2425983C3 (de) * | 1973-06-12 | 1978-09-14 | Toyama Chemical Co. Ltd., Tokio | Sulfonsäuresalze von Acylcholinen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
BR8007911A (pt) | 1979-12-06 | 1981-06-16 | Glaxo Group Ltd | Inalador aperfeicoado |
CY1492A (en) | 1981-07-08 | 1990-02-16 | Draco Ab | Powder inhalator |
NO166268C (no) | 1985-07-30 | 1991-07-03 | Glaxo Group Ltd | Innretning for administrering av medikamenter til pasienter. |
US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
SK280968B6 (sk) | 1990-03-02 | 2000-10-09 | Glaxo Group Limited | Balenie medikamentu na použite v inhalačnom prístroji |
US6006745A (en) | 1990-12-21 | 1999-12-28 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
WO1992022286A1 (en) | 1991-06-12 | 1992-12-23 | Minnesota Mining And Manufacturing Company | Albuterol sulfate suspension aerosol formulations |
US5337740A (en) | 1991-08-01 | 1994-08-16 | New England Pharmaceuticals, Inc. | Inhalation devices |
EP0717987B1 (en) | 1991-12-18 | 2001-08-29 | Minnesota Mining And Manufacturing Company | Suspension aerosol formulations |
US5239993A (en) | 1992-08-26 | 1993-08-31 | Glaxo Inc. | Dosage inhalator providing optimized compound inhalation trajectory |
US5415162A (en) | 1994-01-18 | 1995-05-16 | Glaxo Inc. | Multi-dose dry powder inhalation device |
EP0747355A4 (en) | 1994-02-10 | 1997-04-09 | Yamanouchi Pharma Co Ltd | NEW CARBAMATES AND MEDICINAL PRODUCTS CONTAINING THEM |
US5983956A (en) | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
US5637820A (en) * | 1995-01-06 | 1997-06-10 | Wittman; Kenneth L. | Stringed instrument with on-board tuner |
SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
NZ306280A (en) | 1995-04-14 | 1999-07-29 | Glaxo Wellcome Inc | Metered dose inhaler for salmeterol |
US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
EP1070056B1 (en) | 1998-03-14 | 2004-06-30 | ALTANA Pharma AG | Phthalazinone pde iii/iv inhibitors |
CA2328882A1 (en) | 1998-04-18 | 1999-10-28 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
GB9808802D0 (en) | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
SE9804000D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New composition of matter |
US6693202B1 (en) * | 1999-02-16 | 2004-02-17 | Theravance, Inc. | Muscarinic receptor antagonists |
WO2000061108A1 (en) | 1999-04-14 | 2000-10-19 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
PL393155A1 (pl) | 2001-09-14 | 2011-03-28 | Glaxo Group Limited | Pochodne fenetanoloaminy do leczenia chorób układu oddechowego |
US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
PE20050973A1 (es) * | 2003-10-29 | 2005-11-19 | Theravance Inc | Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos |
TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
TW200540154A (en) * | 2004-06-10 | 2005-12-16 | Theravance Inc | Crystalline form of a substituted pyrrolidine compound |
TWI372749B (en) | 2005-03-10 | 2012-09-21 | Theravance Inc | Crystalline forms of a biphenyl compound |
US20060205949A1 (en) * | 2005-03-10 | 2006-09-14 | Theravance, Inc. | Crystalline forms of a biphenyl compound |
US7465870B1 (en) * | 2008-03-11 | 2008-12-16 | Homan Randy W | Illuminated heart-shaped guitar with strobe lights and a modified bridge |
CA2765621C (en) | 2009-07-15 | 2018-02-13 | Theravance, Inc. | Crystalline freebase forms of a biphenyl compound |
SG186708A1 (en) | 2010-07-13 | 2013-02-28 | Theravance Inc | Process for preparing a biphenyl-2-ylcarbamic acid |
-
2010
- 2010-07-14 CA CA2765621A patent/CA2765621C/en active Active
- 2010-07-14 BR BR112012000890A patent/BR112012000890A2/pt not_active Application Discontinuation
- 2010-07-14 EP EP10732616.7A patent/EP2453894B1/en active Active
- 2010-07-14 ES ES15178848.6T patent/ES2639642T3/es active Active
- 2010-07-14 PT PT107326167T patent/PT2453894E/pt unknown
- 2010-07-14 PL PL15178848T patent/PL2987490T3/pl unknown
- 2010-07-14 ES ES10732616.7T patent/ES2557553T3/es active Active
- 2010-07-14 AU AU2010273514A patent/AU2010273514B2/en active Active
- 2010-07-14 US US12/835,964 patent/US8541451B2/en active Active
- 2010-07-14 SI SI201031095T patent/SI2453894T1/sl unknown
- 2010-07-14 PL PL10732616T patent/PL2453894T3/pl unknown
- 2010-07-14 JP JP2012520734A patent/JP5651174B2/ja active Active
- 2010-07-14 KR KR1020127004005A patent/KR101742252B1/ko active IP Right Grant
- 2010-07-14 HU HUE10732616A patent/HUE026414T2/hu unknown
- 2010-07-14 EP EP15178848.6A patent/EP2987490B1/en active Active
- 2010-07-14 WO PCT/US2010/041903 patent/WO2011008809A1/en active Application Filing
- 2010-07-14 SG SG2012003067A patent/SG178036A1/en unknown
- 2010-07-14 SG SG10201407913UA patent/SG10201407913UA/en unknown
- 2010-07-14 DK DK10732616.7T patent/DK2453894T3/en active
- 2010-07-14 CA CA2989129A patent/CA2989129C/en active Active
- 2010-07-14 MX MX2012000682A patent/MX2012000682A/es active IP Right Grant
- 2010-07-14 CN CN2010800304581A patent/CN102470130B/zh active Active
-
2011
- 2011-12-15 IL IL216995A patent/IL216995A/en active IP Right Grant
-
2012
- 2012-09-13 HK HK12108950.7A patent/HK1168050A1/zh unknown
-
2013
- 2013-08-22 US US13/973,174 patent/US8921396B2/en active Active
-
2014
- 2014-10-07 JP JP2014206123A patent/JP6338505B2/ja active Active
- 2014-11-19 US US14/547,455 patent/US9226896B2/en active Active
-
2015
- 2015-11-04 JP JP2015216372A patent/JP2016026214A/ja active Pending
- 2015-12-01 US US14/955,515 patent/US9415041B2/en active Active
- 2015-12-08 HR HRP20151344TT patent/HRP20151344T1/hr unknown
-
2016
- 2016-01-20 SM SM201600019T patent/SMT201600019B/it unknown
- 2016-06-24 HK HK16107421.6A patent/HK1219415A1/zh unknown
- 2016-07-11 US US15/206,877 patent/US9765028B2/en active Active
-
2017
- 2017-07-10 JP JP2017134632A patent/JP2017171692A/ja active Pending
- 2017-08-15 US US15/677,264 patent/US10100013B2/en active Active
-
2018
- 2018-09-13 US US16/130,079 patent/US10550081B2/en active Active
-
2019
- 2019-12-16 US US16/715,225 patent/US11008289B2/en active Active
-
2021
- 2021-04-15 US US17/301,820 patent/US11691948B2/en active Active
-
2022
- 2022-06-15 US US17/841,567 patent/US11649209B2/en active Active
-
2023
- 2023-05-19 US US18/199,812 patent/US11858898B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1254977A1 (zh) | 索非布韋(sofosbuvir)的結晶形式 | |
HK1219415A1 (zh) | 聯苯化合物的結晶游離碱形式 | |
ZA201105462B (en) | Crystalline insulin-conjugates | |
SG10201500451TA (en) | Crystalline forms of a purine derivative | |
ZA201107772B (en) | Substituted spiro-amide compounds | |
EP2519525A4 (en) | SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS | |
EP2519522A4 (en) | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | |
EP2423182A4 (en) | DIACYLETHYLENEDIAMINE COMPOUND | |
PT2611779T (pt) | Formas cristalinas de um inibidor do fator xa | |
IL216648A0 (en) | Crystalline forms of febuxostat | |
GB0903759D0 (en) | Compound | |
EP2477628A4 (en) | PREPARATION OF CRYSTALLINE FORMS OF DIHYDROPYRAZOLOPYRIMIDINONE | |
GB0914767D0 (en) | Compound | |
SI2358676T1 (sl) | Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine | |
ZA201205726B (en) | Substituted naphthalenyl-pyrimidine compounds | |
EP2505585A4 (en) | BIS benzoxazinone CONNECTION | |
GB0902406D0 (en) | Crystalline polymorphic form | |
GB0909213D0 (en) | Compound | |
ZA201202097B (en) | Crystalline forms of substituted pyrazolopyrimidines | |
ZA201104319B (en) | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | |
GB0914883D0 (en) | Compound | |
ZA201300154B (en) | Crystalline form of a 3-phenoxymethylpyrrolidine compound | |
EP2487178A4 (en) | PYRAZOLOTHIAZOLVERBINDUNG | |
HUP0800755A2 (en) | Crystalline forms of rosiglitazone | |
EP2502926A4 (en) | COMPOUND |